COVAXIN vs COVISHIELD VACCINES:Detailed explanation of Controversy- Govt Justification- Beneficiaries-Doses etc
It doesn't Matter which Vaccine will going to Administer to the People, what really Matter is the Efficacy and Safety.
Vaccine Regulator in India has given Approval to Covaxin, and Covishield Vaccine Candidate for the Inoculation drive which is going to the World's Biggest Vaccination Programme against COVID-19. Both Vaccines are approved for Restricted Emergency Use. PM Mr. Modi praises Scientists and Technicians for the 'Made In India' Vaccines.
Covishield Vaccine, Made by Serum Institute of India(SII) based on Pune is developed by Oxford University and Marketed by AstraZeneca. Covaxin Vaccine, Indigenously made and developed by Bharat Biotect in collaboration with Indian Council of Medical Research(ICMR). Fr more detail visit the site-https://pandemic365.blogspoot.com/2021/01/covid-19-vaccination-covishield-vaccine.htmlc-velocity of speed
SII's Vaccine, Covishield, is based on a Chimpanzee Adenovirus. whereas, Covaxin is a whole inactivated virus, the oldest technology in Vaccine development and current report has claimed that it will going to produce a strong Immune Response in Animals but there is no data yet available suggesting its efficacy. For mutation related detail visit site-https://pandemic365.blogspot.com/2020/12/mutation-in-corona-virus-reasons-of.html
Controversy:
Hasty approval to the indigenously developed Covaxin along with Covishield Vaccine, since Vaccine developed by both the companies haven't gone through all the required tests which includes Trials and whether the Vaccine is effective in Indians. According to the permission notices made public, Covaxin has to finish its phase-1, phase-2 and phase-3 trials and summit updated safety, immunogenicity and efficacy data. US based Pfizer Moderna and UK based Oxford-AstraZeneca have shared data publicly about the trial and efficacy of their Vaccine Candidates. AstraZeneca has promised not to profit from Vaccine during Pandemic. Scientist and Experts have raised alarm, with some saying that lack of efficacy data for Covaxin means it doesn't pass a key requirement of vaccine approval.
Govt Justification:
-Govt has justified the approval on the grounds that the vaccine employs a whole inactivated virus and therefore had a better probability of providing protection against mutated strains.
-SII and Bharat BioTech are expected to submit reports every 15 days on adverse events among those vaccinated if any, for two months. After this, they would have to submit such reports once a month.
-10 million Covaxin Doses ready for the Vaccination against COVID-19- announced by Bharat Biotech Chief.
Beneficiaries:
Free Vaccination will be provided to three crore Health care workers in the first phase of vaccination claimed by Health Minister, further, he added that details of 27 crores priority beneficiaries those above 50 years of age and those below it having co-morbidities is also being finalized. For Registration related info. visit the site-https://pandemic365.blogspot.com/2020/12/coronavirus-or-covid-19-vaccination.html
Comments
Post a Comment